- Page 2:
HANDBOOK OFSOPs FOR GOODCLINICAL PR
- Page 10:
About PolarisClinical Research Cons
- Page 14:
Table of ContentsMON-001.0MON-002.0
- Page 18:
Initial SubIRB MemberMinutes Templa
- Page 22:
SOP# MON-001.0CompanyEffective Date
- Page 26:
CompanyStandard Operating Procedure
- Page 30:
SOP# MON-002.0CompanyEffective Date
- Page 34:
CompanyStandard Operating Procedure
- Page 38:
SOP# MON-003.0CompanyEffective Date
- Page 42:
SOP# MON-004.0CompanyEffective Date
- Page 46:
SOP# MON-004.0CompanyEffective Date
- Page 50:
SOP# MON-005.0CompanyEffective Date
- Page 54:
SOP# MON-005.0CompanyEffective Date
- Page 58:
SOP# MON-006.0CompanyEffective Date
- Page 62:
SOP# MON-006.0CompanyEffective Date
- Page 66:
CompanyStandard Operating Procedure
- Page 70:
SOP# MON-007.0CompanyEffective Date
- Page 74:
SOP# MON-007.0CompanyEffective Date
- Page 78:
CompanyStandard Operating Procedure
- Page 82:
SOP# MON-008.0CompanyEffective Date
- Page 86:
SOP# MON-008.0CompanyEffective Date
- Page 90:
SOP# MON-009.0CompanyEffective Date
- Page 94:
SOP# MON-009.0CompanyEffective Date
- Page 98:
SOP# MON-009.0CompanyEffective Date
- Page 102:
SOP# MON-009.0CompanyEffective Date
- Page 106:
SOP# MON-009.0CompanyEffective Date
- Page 110:
SOP# MON-009.0CompanyEffective Date
- Page 114:
SOP# MON-010.0CompanyEffective Date
- Page 118:
SOP# MON-010.0CompanyEffective Date
- Page 122:
CompanyStandard Operating Procedure
- Page 126:
SOP# MON-011.0CompanyEffective Date
- Page 130:
CompanyStandard Operating Procedure
- Page 134:
SOP# MON-012.0CompanyEffective Date
- Page 138:
SOP# MON-012.0CompanyEffective Date
- Page 142:
CompanyStandard Operating Procedure
- Page 146:
CompanyStandard Operating Procedure
- Page 150:
SOP# SITE-001.0CompanyEffective Dat
- Page 154:
SOP# SITE-002.0CompanyEffective Dat
- Page 158:
SOP# SITE-002.0F. Retention of Trai
- Page 162:
SOP# SITE-003.0CompanyEffective Dat
- Page 166:
SOP# SITE-004.0CompanyEffective Dat
- Page 170:
SOP# SITE-005.0CompanyEffective Dat
- Page 174:
SOP# SITE-006.0CompanyEffective Dat
- Page 178:
SOP# SITE-006.0CompanyEffective Dat
- Page 182: SOP# SITE-007.0CompanyEffective Dat
- Page 186: CompanyStandard Operating Procedure
- Page 190: SOP# SITE-008.0CompanyEffective Dat
- Page 194: CompanyStandard Operating Procedure
- Page 198: SOP# SITE-009.0CompanyEffective Dat
- Page 202: SOP# SITE-009.0CompanyEffective Dat
- Page 206: CompanyStandard Operating Procedure
- Page 210: SOP# SITE-010.0CompanyEffective Dat
- Page 214: CompanyStandard Operating Procedure
- Page 218: SOP# SITE-011.0CompanyEffective Dat
- Page 222: CompanyStandard Operating Procedure
- Page 226: CompanyStandard Operating Procedure
- Page 230: SOP# SITE-013.0CompanyEffective Dat
- Page 236: CompanyStandard Operating Procedure
- Page 240: SOP# SITE-014.0F. Records Retention
- Page 244: CompanyStandard Operating Procedure
- Page 248: SOP# IRB-001.0CompanyEffective Date
- Page 252: SOP# IRB-002.0CompanyEffective Date
- Page 256: SOP# IRB-002.0E. IRB SecretaryCompa
- Page 260: SOP# IRB-002.0CompanyEffective Date
- Page 264: SOP# IRB-003.0CompanyEffective Date
- Page 268: SOP# IRB-003.0F. VotingCompanyEffec
- Page 272: CompanyStandard Operating Procedure
- Page 276: SOP# IRB-004.0CompanyEffective Date
- Page 280: SOP# IRB-005.0CompanyEffective Date
- Page 284:
SOP# IRB-005.0CompanyEffective Date
- Page 288:
CompanyStandard Operating Procedure
- Page 292:
SOP# IRB-006.0CompanyEffective Date
- Page 296:
SOP# IRB-006.0CompanyEffective Date
- Page 300:
SOP# IRB-007.0CompanyEffective Date
- Page 304:
CompanyStandard Operating Procedure
- Page 308:
SOP# IRB-008.0CompanyEffective Date
- Page 312:
SOP# IRB-009.0CompanyEffective Date
- Page 316:
SOP# IRB-009.0CompanyEffective Date
- Page 320:
CompanyAdvertisement Review Checkli
- Page 324:
CompanyBiological Samples Inventory
- Page 328:
CompanyData Clarification FormCompo
- Page 332:
CompanyStudy Subject Investigationa
- Page 336:
CompanyInvestigational Drug Shippin
- Page 340:
CompanyDrug Return FormDrug name: S
- Page 344:
CompanyScreening and Enrollment Log
- Page 348:
CompanyInformed ConsentExpedited Re
- Page 352:
CompanySubject Information and Cons
- Page 356:
CompanyStudy Initiation Document Tr
- Page 360:
CompanyInitial Submission FormStudy
- Page 364:
CompanyInitial Submission Form (con
- Page 368:
CompanyInitial Submission Form (con
- Page 372:
CompanyInitial Submission Form (con
- Page 376:
CompanyIRB MEETING MINUTES TEMPLATE
- Page 380:
CompanyAMENDMENTSPrincipal Investig
- Page 384:
CompanyMonitoring LogProtocol #: In
- Page 388:
SubjectnumberSubject Name and Addre
- Page 392:
CompanyIRB Progress Report FormProt
- Page 396:
CompanyStudy Responsibilities FormP
- Page 400:
CompanyReviewer’s ChecklistProtoc
- Page 404:
CompanyIRB Review Results FormPropo
- Page 408:
Code INTENSITY as:1 = Mild2 = Moder
- Page 412:
CompanySerious Adverse Subject Init
- Page 416:
CompanySafety Information FormProto
- Page 420:
CompanyStudy Signature Sheet (contd
- Page 424:
CompanyIRB Notification of Study Te
- Page 428:
CompanyTraining Plan FormEmployee:S
- Page 432:
CompanyEmployeeProject-specific tra
- Page 436:
CompanyStaff Training Request FormE
- Page 440:
CompanySite Evaluation Visit Trip R
- Page 444:
CompanyOverall Assessment (continue
- Page 448:
CompanyMEETING CONTENTINDICATE WHIC
- Page 452:
CompanyPeriodic Site Visit Trip Rep
- Page 456:
CompanySERIOUS ADVERSE EXPERIENCESS
- Page 460:
CompanyStudy Termination Visit Trip
- Page 464:
CompanyStudy Drug (continued)Yes No
- Page 468:
CompanyMeeting with InvestigatorDid